At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRVO CervoMed
Pre-Mkt 09-25 06:17:55 EDT
2.52
+0.01
+0.40%
盘前2.45
-0.07-2.78%
04:49 EDT
High2.53Low2.43Vol91.01K
Open2.46D1 Closing2.51Amplitude3.98%
Mkt Cap38.10MTradable Cap24.20MTotal Shares15.12M
T/O226.18KT/O Rate0.95%Tradable Shares9.60M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CervoMed Joins ROTH Healthcare Opportunities Conference Neuroscience Panel
Reuters  ·  09-22 19:31
CervoMed Joins ROTH Healthcare Opportunities Conference Neuroscience Panel
CervoMed highlights late-breaking neflamapimod Phase 2a data
TIPRANKS  ·  09-11
CervoMed highlights late-breaking neflamapimod Phase 2a data
CervoMed Neflamapimod Phase 2a nfvPPA Biomarker Data Set for ISFTD 2026 Oral Session
Reuters  ·  09-10
CervoMed Neflamapimod Phase 2a nfvPPA Biomarker Data Set for ISFTD 2026 Oral Session
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Have Been Accepted as a Late-Breaking Oral Session at Isftd 2026
THOMSON REUTERS  ·  09-10
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (Nfvppa) Have Been Accepted as a Late-Breaking Oral Session at Isftd 2026
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
GlobeNewswire  ·  09-10
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
CervoMed to Participate in September Investor Conferences
GlobeNewswire  ·  09-08
CervoMed to Participate in September Investor Conferences
CervoMed price target lowered to $7 from $9 at Roth Capital
TIPRANKS  ·  08-20
CervoMed price target lowered to $7 from $9 at Roth Capital
CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
Dow Jones  ·  08-12
CervoMed Price Target Maintained with a $25.00/Share by HC Wainwright & Co.
CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained
TIPRANKS  ·  08-12
CervoMed: Buy Rating Reiterated as Dementia Pipeline Advances; $25 Price Target Maintained
CervoMed is Maintained at Buy by Canaccord Genuity
Dow Jones  ·  08-10
CervoMed is Maintained at Buy by Canaccord Genuity
CervoMed Q2 Net Loss Lower than Estimates as Costs Drop
Reuters  ·  08-10
CervoMed Q2 Net Loss Lower than Estimates as Costs Drop
CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate
Benzinga Earnings  ·  08-10
CervoMed Q2 EPS $(0.64) Misses $(0.60) Estimate
Press Release: CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Dow Jones  ·  08-10
Press Release: CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-08
CervoMed Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Cervomed Q2 FY26 Net Loss Widens 5% to $6.57 Million; Revenue Turns to None
Reuters  ·  08-08
Cervomed Q2 FY26 Net Loss Widens 5% to $6.57 Million; Revenue Turns to None
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire  ·  08-05
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
CervoMed Inc Expected to Post a Loss of 87 Cents a Share - Earnings Preview
Reuters  ·  08-04
CervoMed Inc Expected to Post a Loss of 87 Cents a Share - Earnings Preview
CervoMed’s neflamapimod gains UK Innovation Passport
TIPRANKS  ·  08-04
CervoMed’s neflamapimod gains UK Innovation Passport
CervoMed Says UK Grants ILAP Innovation Passport for Neflamapimod in Lewy Body Dementia
Reuters  ·  08-04
CervoMed Says UK Grants ILAP Innovation Passport for Neflamapimod in Lewy Body Dementia
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (Ilap) for Treatment of Dementia with Lewy Bodies (Dlb)
THOMSON REUTERS  ·  08-04
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (Ilap) for Treatment of Dementia with Lewy Bodies (Dlb)

Introduction

Company Name.
CervoMed
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Issue price:
--